• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
AMG 386 (Ovarian Cancer) - Analysis and Forecasts to 2020 - Product Image

AMG 386 (Ovarian Cancer) - Analysis and Forecasts to 2020

  • ID: 2114421
  • September 2011
  • 32 pages
  • GlobalData

AMG 386 (Ovarian Cancer) - Analysis and Forecasts to 2020

Summary

GlobalData’s pharmaceuticals report, "AMG 386 (Ovarian Cancer) - Analysis and Forecasts to 2020” provides AMG 386 sales forecasts for the US, EU and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2015-2020). The report also includes information on Ovarian Cancer market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

- Therapy area profile including patient population for the US, EU and Japan (seven major markets)
- Analysis and review of AMG 386 including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- READ MORE >

1
1

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Ovarian Cancer
2.2 Ovarian Cancer Market
2.3 Epidemiology
2.4 Etiology
2.4.1 Age
2.4.2 Inherited Gene Mutations
2.4.3 A Previous Cancer Diagnosis
2.4.4 Early Menstruation or Late menopause
2.4.5 Family History of Ovarian Cancer
2.5 GlobalData Market Forecasts Report Guidance
3 Ovarian Cancer: Market Characterization
3.1 Ovarian Cancer Market
3.2 Ovarian Cancer Market Forecasts and CAGR
3.3 Drivers for Ovarian Cancer Market
3.3.1 High Incidence
3.3.2 High Mortality Rate
3.3.3 Increased Use of Chemotherapy in Ovarian Cancer
3.3.4 Emergence of Targeted Therapy Drugs
3.3.5 Recurrence of Tumor
3.3.6 Low Initial Diagnosis Rate
4 Tumor-Node-Metastases (TNM) Classification of Ovarian Cancer
5 AMG 386
5.1 Introduction
5.2 Mechanism of Action
5.3 Clinical Studies
5.4 Factors Affecting Sales of AMG 386
5.4.1 First Mover Advantage
5.4.2 AMG 386 in Combination with Avastin
5.4.3 Safety and Toxicity Profile
5.5 Drug Evaluation
5.5.1 Drug Risk Benefit Score
5.5.2 Relative Efficacy
5.5.3 Safety
5.5.4 Compliance
5.5.5 Dosing Convenience
5.5.6 Intensity of Competition
5.6 Sales Forecasts
5.6.1 Target Patient Pool of AMG 386
5.6.2 Dosing
5.6.3 Market Penetration
5.6.4 Annual Cost of Therapy
5.6.5 Sales Projections of AMG 386
6 Ovarian Cancer Market: Appendix
6.1 Market Definitions
6.2 Abberiviations
6.3 Research Methodology
6.3.1 Coverage
6.3.2 Secondary Research
6.3.3 Forecasting
6.3.4 Number of Patients Approved to take the Drug
6.3.5 Net Penetration of Drug
6.3.6 Net Annual Dosing
6.3.7 Annual Cost of Therapy
6.4 Drug Sales Estimates Model
6.5 Contact Us
6.6 Disclaimer
6.7 Sources

1.1 List of Tables
Table 1: Ovarian Cancer, Incidences and Mortality, 2008–2030
Table 2: Detailed TNM Classification
Table 3: Drug Risk Benefit Score of AMG 386
Table 4: Annual Cost of Therapy of AMG 386, 2015
Table 5: AMG 386, Ovarian Cancer, Global, Sales Forecasts ($m), 2015–2020
Table 6: AMG 386, Ovarian Cancer, The US, Sales Forecasts ($m), 2015–2020
Table 7: AMG 386, Ovarian Cancer, The UK, Sales Forecasts ($m), 2015–2020
Table 8: AMG 386, Ovarian Cancer, France, Sales Forecasts ($m), 2015–2020
Table 9: AMG 386, Ovarian Cancer, Germany, Sales Forecasts ($m), 2015–2020
Table 10: AMG 386, Ovarian Cancer, Italy, Sales Forecast ($m), 2015–2020
Table 11: AMG 386, Ovarian Cancer, Spain, Sales Forecasts ($m), 2015–2020
Table 12: AMG 386, Ovarian Cancer, Japan, Sales Forecasts ($m), 2015–2020

1.2 List of Figures
Figure 1: Distribution by Incidence and Mortality, Most Frequently Diagnosed Cancers, Worldwide, 2010
Figure 2: Ovarian Cancer, Global, Market Size Forecasts ($bn), 2010–2020
Figure 3: Ovarian Cancer, Worldwide, Incidence (million), 2008-2030
Figure 4: Oncology, Worldwide, Incidence (million), 2008-2030
Figure 5: Ovarian Cancer, Worldwide, Mortality (million), 2008-2030
Figure 6: Broad Classification of Ovarian Cancer
Figure 7: Classification of Ovarian Cancer
Figure 8: Drug Model Diagram of AMG 386
Figure 9: AMG 386, Ovarian Cancer, Global, Sales Forecasts ($m), 2015–2020
Figure 10: AMG 386, Ovarian Cancer , The US, Sales Forecasts ($m), 2015–2020
Figure 11: AMG 386, Ovarian Cancer, The UK, Sales Forecasts ($m), 2015–2020
Figure 12: AMG 386, Ovarian Cancer, France, Sales Forecasts ($m), 2015–2020
Figure 13: AMG 386, Ovarian Cancer, Germany, Sales Forecasts ($m), 2015–2020
Figure 14: AMG 386, Ovarian Cancer, Italy, Sales Forecasts ($m), 2015–2020
Figure 15: AMG 386, Ovarian Cancer, Spain, Sales Forecasts ($m), 2015–2020
Figure 16: AMG 386, Ovarian Cancer, Japan, Sales Forecasts ($m), 2015–2020
Figure 17: AMG 386, Ovarian Cancer, Global, Sales Distribution by Country (%), 2020
Figure 18: Patients Approved for the Drug

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos